Last update Dec. 18, 2020
Hemostatic drug which has a possible protective effect on the capillary wall along with correction of altered platelet adhesion.
It is used in Menometrorrhagia (Lethaby 2013), prophylaxis on surgical wounds and neonatal intraventricular hemorrhage without a solid evidence of its effictiveness (Hunt 2010, Kuperman 2015).
It is orally, intramuscularly and intravenously administered every 4 - 6 hours for 3 - 4 days.
At latest update relevant published data on excretion into breast milk were not found.
Its high capacity of binding to plasma proteins makes it unlikely a excretion into breast milk.
Due to low frequency and mildness of eventual side effects and/or absence of interference with coagulation mechanisms, seems unlikely this product would affect breastfeeding or the infant.
We do not have alternatives for Etamsylate.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM